Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | TTR | P02766 | 2/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.41 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.41 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.41 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3636581 | 0.98 | KMT2A (0.42) | KMT2AMEN1MAPTPTK2BNPC1 | |
| SCHEMBL28535131 | 0.98 | KMT2A (0.42) | KMT2AMEN1MAPTPTK2BNPC1 | |
| SCHEMBL7164936 | 0.84 | MEN1 (0.54) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL6243396 | 0.78 | CYP19A1 (0.46) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL8370090 | 0.77 | KMT2A (0.57) | KMT2AMAPTTTRAKR1B10UGT1A9 | |
| SCHEMBL7759545 | 0.77 | HTT (0.45) | KMT2ARAB9ATTRAKR1B10UGT1A9 | |
| SCHEMBL6243149 | 0.77 | MEN1 (0.51) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL8365425 | 0.77 | KMT2A (0.50) | KMT2AMEN1TTRAKR1B10UGT1A9 | |
| SCHEMBL27926510 | 0.75 | CYP19A1 (0.47) | KMT2AMEN1MAPTRAB9ALMNA | |
| SCHEMBL16672098 | 0.75 | KMT2A (0.58) | KMT2AMEN1MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210353579-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO LTD (CN) | 2021-11-18 | — | — | US | disclosed |
| EP-2756843-A2 | Positively charged water-soluble prodrugs of diclofenac with very fast skin penetration rate | Techfields Biochem Co. Ltd (CN) | 2014-07-23 | — | — | EP | disclosed |
| EP-2046727-B1 | POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF DICLOFENAC WITH VERY FAST SKIN PENETRATION RATE | TECHFIELDS BIOCHEM CO LTD (CN) | 2014-03-12 | — | — | EP | disclosed |
| WO-2010065936-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | YU CHONGXI (US) | 2010-06-10 | — | — | WO | disclosed |
| EP-2046727-A1 | POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF DICLOFENAC WITH VERY FAST SKIN PENETRATION RATE | Techfields Biochem Co. Ltd (CN) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008012602-A1 | POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF DICLOFENAC WITH VERY FAST SKIN PENETRATION RATE | TECHFIELDS BIOCHEM CO. LTD (CN) | 2008-01-31 | — | — | WO | disclosed |
| EP-1558559-A1 | MANUFACTURING PROCESS FOR NO-DONATING COMPOUNDS SUCH AS NO-DONATING DICLOFENAC | Nicox S.A. (FR) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004026808-A1 | MANUFACTURING PROCESS FOR NO-DONATING COMPOUNDS SUCH AS NO-DONATING DICLOFENAC | NICOX SA. (FR) | 2004-04-01 | — | — | WO | disclosed |
| WO-2003068203-A1 | USE OF A COMBINATION OF A NON-STEROIDAL ANTI-INFLAMMATORY AGENT AND GUAIFENESIN FOR THE TREATMENT OF ACUTE PAIN | ZENTIVA, A.S. (CZ) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353579-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | KMT2A 3616/4885MEN1 4272/4885MAPT 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.